The discovery of a specific prorenin receptor (PRR) suggests a biological function of prorenin that is independent of angiotensin I production. In the present study, we investigated the role of PRR on smooth muscle cell (SMC) migration.
Introduction
Renin, a key regulatory enzyme of the renin-angiotensin system, 1 is an aspartyl protease synthesized and secreted as an inactive proenzyme, prorenin, characterized by a 43-amino-acid pro-segment that covers the cleft of the active site. Prorenin, which represents up to 90% of total renin in human plasma, had been considered to have no biological activity until the discovery of its specific receptor, prorenin receptor (PRR). Prorenin binds PRR three times more efficiently than renin, 2, 3 and after the binding its catalytic site is unmasked, resulting in a full activation of this pro-enzyme. 4 The binding of prorenin to the PRR may thus explain its non-proteolytic activation observed in human tissues. 5 PRR is expressed in the subendothelium of coronary arteries and, more precisely, in smooth muscle cells (SMCs). 4, 6 Although the role of this receptor in vascular pathophysiology still needs to be elucidated fully, some evidence that PRR activity may be involved in cardiovascular diseases comes from in vivo studies using transgenic rats. Transgenic rats with exclusive PRR overexpression in SMCs develop a cardiac phenotype with elevated systolic blood pressure and heart rate. 7 Alternatively, when PRR is ubiquitously overexpressed, rats develop proteinuria and progressive nephropathy. 8 The direct role of PRR, independent from the renin-angiotensin system, on this phenotype was demonstrated through a specific inhibition of prorenin binding to PRR with the infusion of the handle region decoy peptide. 8 Binding of prorenin to PRR triggers intracellular signals associated with the activation of mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases (ERK1 and ERK2), and phosphorylation of heat shock protein 27 (HSP27), leading to enhanced DNA synthesis and cell contractility. 8 -10 The domains of PRR interacting with prorenin have only been hypothesized, 2 although it has been demonstrated that the active site of renin is not involved, because the direct renin inhibitor aliskiren has no effect on prorenin binding to PRR. 9 Nevertheless, aliskiren has been demonstrated to affect the expression of PRR both in vivo and in vitro, and, in turn, the transcription of the profibrotic molecules transformin growth factor-b, plasminogen activator inhibitor-1 and type I collagen. 11, 12 Although the effect of prorenin and PRR on cell proliferation and contractility has recently begun to emerge, no information is available on the role of PRR on cell migration. Thus, in the present study we tested the hypothesis that prorenin, through the PRR, may induce SMC migration, and we investigated the basic molecular mechanism of this action.
Methods
For detailed descriptions of the Materials and Methods, please see Supplemental materials.
Cell culture
Aortic human SMCs were purchased from PromoCell GmbH (Heidelberg, Germany) and cultured in Smooth Muscle Cell Growth Medium (PromoCell GmbH, Heidelberg, Germany) 2 supplemented with 5% fetal calf serum (FCS), 0.5 ng/mL of epidermal growth factor, 2 ng/mL of basic fibroblast growth factor, and 5 mg/mL of insulin. For the experiments, SMCs were starved in Dulbecco's modified Eagle's medium (DMEM) containing 0.4% FCS for 48 h, then stimulated with prorenin or platelet derived growth factor-BB (PDGF-BB) for different times and with concentrations indicated in the figure legends. For the Boyden chamber chemotaxis assay, cells were harvested by trypsinization, resuspended in DMEM with 0.4% FCS, and loaded on the chamber.
Vessel preparations
Segments of human internal mammary arteries were collected from patients undergoing elective coronary artery bypass surgery. Permission to use the discarded internal mammary artery tissue was given by the Ethics Committee of the Centro Cardiologico Monzino. The investigation conforms with the principles outlined in the Declaration of Helsinki. Freshly isolated vessel segments (n ¼ 12) were snap-frozen in liquid nitrogen and stored at -808C until total protein and RNA extraction, which were performed as previously described. 13 
RNA preparation and quantitative real-time PCR analysis
Total RNA was prepared from human mammary artery and cultured SMCs with RNeasy kit (Qiagen, Milan, Italy) and reverse transcribed with the iScript TM cDNA synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). Real-time PCRs were then performed using the TaqMan Gene Expression Assay for human prorenin receptor (assay ID: Hs00997145_m1) and for eukaryotic 18S rRNA (assay ID: Hs03003631_g1) and ABI Prism w 7000 Sequence Detection System (Applied Biosystems, Monza, Italy).
Immunocytochemistry
Immunodetection of PRR was carried out by incubating cells with rabbit polyclonal anti-human ATP6AP2 (Prestige Antibodies, Sigma Aldrich, Milan, Italy) and by using the AlexaFluor 488-labelled goat anti-rabbit IgG (Molecular Probes, Invitrogen, San Giuliano Milanese, Italy). Focal adhesions were stained by paxillin immunostaining with a mouse monoclonal anti-paxillin antibody (BD Transduction Laboratories, Buccinasco, Milan, Italy) followed by incubation with AlexaFluor 488-labelled goat anti-mouse antibody (Molecular Probes).
Western blot analysis
Cells were lysed with a solution of 50 mM Tris (pH 7.5), 150 mM NaCl, and 0.5% Nonidet-P40, containing a protease and phosphatase inhibitor cocktails (Sigma Aldrich, Milan, Italy). Equal amounts of total protein per sample were separated by SDS -PAGE in reducing conditions, transferred to Immobilon PVDF (GE Healthcare, Little Chalfont, UK), and subsequently immunoblotted with primary antibody following an appropriate secondary antibody, prior to visualization by enhanced chemiluminescence (LiteAblot Extend Long Lasting Chemiluminescent Substrate, EuroClone, Milan, Italy). Quantitative densitometric analyses were performed using a Gel Doc acquisition system and Quantity One software (Bio-Rad Laboratories).
Cell migration assay
The Boyden chamber and the polycarbonate membrane were purchased from Biomap (Agrate Brianza, Milan, Italy). The membranes were coated with 0.1 mg/mL of type I collagen solution (PureCol w , Nutacon BV, Leimuiden, The Netherlands) in 0.1 M acetic acid at 378C. The lower compartments of the wells of a modified Boyden chamber were filled (in triplicate) with DMEM containing 0.4% FCS in the absence or presence of prorenin or PDGF-BB, whereas the upper compartments were filled with aliquots of the SMC suspensions containing 10 6 cells/mL. The chamber was incubated at 378C for 6 h. The membrane was then carefully removed. Adherent SMCs on the top were eliminated, and the membrane was stained with a Diff-Quik staining set (Biomap, Agrate Brianza, Milan, Italy). The number of transmigrated cells was counted in four random high-power fields under high magnification (×20 objective lens). 14 
Video microscopy analysis
Time-lapse video microscopy was performed as described previously, 15, 16 with slight modifications. In brief, cultured SMCs were placed on the stage of an inverted motorized microscope (Axiovert 200M, Zeiss Instruments, Oberkochen, Germany) in a cage incubator (CTI Controller 2700 digital, Zeiss Instruments) at 378C. Phase-contrast images were collected with a ×10 A-Plan lens (Zeiss Instruments) every 15 min over a 16 h period using a camera (AxioCam HRm, Zeiss Instruments) and the Axiovision LE software (Zeiss Instruments). Trajectories were reconstructed according to the recorded data. The distance covered by each cell was extracted from the track plots. Ten cells from three independent experiments were analysed for each condition, and data were expressed as the means + SD.
G-LISA assay for Rac1 and RhoA
The intracellular amounts of Rac1-GTP and RhoA-GTP were determined by using the G proteins-linked immunoSorbent assay (G-LISA) (Cytoskeleton, Inc., Denver, CO, USA). 17 
Cytoskeleton staining
Cells were fixed in 4% paraformaldehyde at room temperature for 10 min, permeabilized in 0.1% Triton X-100 in phosphate-buffered saline for 5 min, and incubated with fluorescein isothiocyanate-phalloidin (Sigma Aldrich, Milan, Italy). Cytoskeleton staining of cells was analysed using a fluorescence microscope (Axiovert M220; Zeiss Instruments).
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Transfection of small interfering RNA
Transfections were performed as previously described using siLentFect TM Lipid Reagent (Bio-Rad Laboratories) according to the manufacturer's protocol. 18 SMCs were seeded at a density of 5 × 10 5 per Petri dish (35 mm) the day before the transfection in completed Smooth Muscle Cell Growth Medium 2. Cells were then transfected with 20 nM of small interfering RNA (siRNA) for 24 h; then, the medium was replaced with DMEM containing 0.4% FCS for an additional 24 h before performing the Boyden chamber chemotaxis assay.
Peptide synthesis
All peptides were synthesized using CEM Liberty peptide synthesizer and purified using reverse-phase high-performance liquid chromatography (RP-HPLC) with a Jasco BS-997-01 instrument and DENALI C-18 column from GRACE VYDAC (Deerfield, IL, USA) (10 mm, 250 mm × 22 mm). Human (RIFLKRMPSI) and scrambled decoy peptides (LIRMRF-PIKS) were prepared by microwave-assisted solid-phase synthesis based on Fmoc chemistry on preloaded 2-chlorotrityl resin (1.5 meqiv/g substitution). All peptides were purified by RP-HPLC and analysed by electrospray ionization (ESI) mass spectroscopy, freeze-dried and stored at 08C.
Statistical analysis
All data shown are representative of at least three replicate experiments. Data are expressed as the means + SD. Statistical analyses were performed using either Student's unpaired t-test or one-way analysis of variance followed by the Dunnett's multiple comparison post hoc test, as appropriate. Values of P , 0.05 were considered significant.
Results

PRR is expressed in human mammary arteries and cultured SMCs
The prorenin receptor was originally discovered in human mesangial cells, and its expression was shown by immunohistochemistry to co-localize with a-actin-positive cells in coronary and kidney arteries in mice. 4 To extend this observation, PRR expression was studied in human mammary arteries from six patients who underwent elective coronary artery bypass surgery. Western blotting analysis with a polyclonal anti-PRR antibody detected a 39 kDa band, corresponding to the molecular weight of PRR ( Figure 1A ). The molecular weight of the protein detected from mammary artery samples was similar to that observed in human embryonic kidney cells (HEK293) utilized as a positive control. 19 Moreover, western blot analysis from total cell lysates of rat SMCs retrovirally overexpressing PRR clearly showed the presence of a specific band with a molecular weight of 39 kDa, further confirming the specificity of the antibody utilized (see Supplementary material online, Figure  SIA) . By RT-PCR analysis, similar expression levels of PRR mRNA were observed in four total RNA extracts of human mammary arteries. These levels were about half of those observed in cultured human SMCs ( Figure 1C ). Immunocytochemistry analysis of cultured human aortic SMCs detected a positive PRR staining in vesicular compartments around the nuclei ( Figure 1D ). C.M. Greco et al.
Prorenin induces human SMC migration and motility
To test the hypothesis that prorenin may act as a chemotactic agent towards SMCs, we performed two different analyses, the Boyden chamber assay and the video microscopy analysis, and utilized PDGF-BB as a positive chemotactic agent. In the first series of experiments, we measured the effect of 10 28 M prorenin on SMC migration 
Chemotactic effect of prorenin is dependent on PRR in human SMCs
To investigate whether the observed chemotactic action of prorenin is dependent on its interaction with PRR, we pursued two different experimental approaches; namely, the first based on the pharmacological inhibition of the prorenin binding to PRR by a decoy peptide, 2 and the second, by down-regulating the PRR expression using siRNA. Incubation of human SMCs with the competitive PRR blocker decoy peptide almost completely abolished the chemotactic response to prorenin ( Figure 3A) . The specific action of this approach was demonstrated by the finding that the chemotactic action of prorenin was not inhibited by a scrambled peptide ( Figure 3B) .
Transfection of human SMCs with siRNA directed to PRR resulted in a 92% reduction of mRNA levels of PRR ( Figure 3C ) , which led to a 70% reduction of PRR protein levels after 48 h transfection ( Figure 3D ). SMCs transfected with siRNA PRR did not respond to the chemotactic action of prorenin, as assessed by Boyden chamber Smooth muscle cell migration and prorenin assay ( Figure 3E ). In contrast, SMCs transfected with scrambled siRNA increased their migratory potential by three-fold in response to prorenin. These results clearly show that the chemotactic action of prorenin depends on the presence of PRR in human SMCs.
Prorenin induces cytoskeleton reorganization in human SMCs
The effect of prorenin on filamentous actin (F-actin) distribution and focal adhesion formation was examined by fluorescein-labelled phalloidin and immunostaining of paxillin, respectively. After 10 min stimulation of SMCs with 10 28 M prorenin, a significant redistribution of F-actin was observed, resulting in the production of lamellipodia and membrane protrusions ( Figure 4A ). The effect of prorenin on RhoA and Rac1 activity was then determined by G-LISA at different time points. A significant increase of both RhoA-GTP and Rac1-GTP intracellular concentrations (38.0 and 43.0%, respectively) was observed after 30 min stimulation ( Figure 4B ). After 60 min, the RhoA-GTP concentration returned to basal levels, while Rac1-GTP was still partly active. In order to determine whether the effect of prorenin on Rho proteins was dependent on PRR, the intracellular levels of Rac1-GTP and RhoA-GTP were measured by G-LISA, in SMCs transfected with scrambled siRNA (control) and siRNA directed to PRR. After 30 min stimulation, a significant increase of both Rac1 and RhoA activity was observed in control cells, while SMCs transfected with siRNA PRR did not respond ( Figure 4C and D) . The requirement of both Rac1 and RhoA GTP small proteins for the prorenin chemotactic effect on SMCs was first assessed by using two selective chemical inhibitors for Rac1 and RhoA. 17, 20 The chemotactic response to prorenin was inhibited in a concentrationdependent manner by both inhibitors (see Supplementary material online, Figure SIIA ). More specifically, Rac1 and RhoA proteins were inhibited by transfecting SMCs with validated Silencer Select Pre-designed siRNAs. 18 The effect of siRNA was assessed by the determination of intracellular GTP-bound active forms of both Rac1 and RhoA by G-LISA. In SMCs transfected with scrambled siRNA, prorenin increased the intracellular levels of both Rac1-GTP and RhoA-GTP by 36.7 and 47.8%, respectively. This effect was completely abrogated in cells transfected with siRNA directed to either Rac1 or RhoA (see Supplementary material online, Figure SIIB and C ). In these conditions, a complete inhibition of the chemotactic effect of prorenin was observed, suggesting that both Rac1 and RhoA activation are required for SMC migration ( Figure 4E ).
Prorenin induces pp125 FAK cleavage in human SMCs
To investigate the basic molecular mechanism underlying the chemotactic effect of prorenin further, the morphology of focal adhesions was studied by immunocytochemistry analysis with an anti-paxillin antibody. SMCs stimulated at various time points with prorenin showed a significant increase (+42.8 + 23.0%) in the size of focal adhesions after 10 min ( Figure 5A and B) .
Western blot analysis with an anti-focal adhesion kinase (pp125 FAK ) antibody of total protein extracts from human SMCs incubated with prorenin for 60 min showed the presence of two major cleavage products of pp125
FAK with molecular weights of approximately of 90 and 50 kDa. In contrast, PDGF-BB failed to induce the cleavage of pp125 FAK ( Figure 5C ). Time course experiments showed that the formation of the two pp125 FAK fragments was observed after approximately 60 min stimulation with prorenin and tended to return to basal levels at later time points ( Figure 5D ).
pp125 FAK processing is required for migration of human SMCs in response to prorenin
Calpain-mediated pp125 FAK cleavage was previously reported in different experimental conditions. 21, 22 We therefore explored the possibility that the formation of the two pp125 Figure SIIIB) . The inhibition of ERK activity was previously shown to affect endothelial cell migration, measured using a wound healing assay, in response to prorenin. 24 In order to determine the role of ERK on the chemotactic effect of prorenin on SMCs, we evaluated cell migration in the presence or absence of the MAPK/ERK kinase inhibitor PD98059. As expected, the incubation with 10 25 M PD98059
completely inhibited the ERK phosphorylation in SMCs stimulated with either prorenin or PDGF-BB (see Supplementary material online, Figure SIIB) . Incubation with the same concentration of PD98059 did not affect the migration of SMCs (see Supplementary material online, Figure SIIIC ) , excluding a role for ERK in prorenindependent SMC migration.
Discussion
In the present study, both the expression of the PRR and the potential chemotactic effect of prorenin were investigated in human mammary arteries and cultured SMCs. The PRR was initially discovered to be expressed in human mesangial cells, 6 and to be present in the tunica media of mouse coronary and kidney arteries. 4 By western blot analysis of total protein extracts of six different specimens of human mammary arteries, and by quantitative RT-PCR from total RNA, we demonstrated that PRR is also expressed in human mammary artery. Although PRR in human arteries could not be detected by immunohistochemistry analysis with the commercially available antibodies (data not shown), cultured human aortic SMCs clearly expressed PRR. Previous studies indicated that PRR was not present in endothelial cells but only in SMCs, 4 cardiomyocytes, 25 and monocytes. 9 Thus, from these analyses it is feasible to conclude that PRR is present in SMCs of normal human arteries. The potential effect of prorenin on SMCs migration was first hypothesized by the fact that prorenin was previously shown to regulate the phosphorylation state of HSP27, 25 a protein involved in SMC contractility, cytoskeleton organization and cell migration. 26 By
Boyden chamber chemotaxis assay and video microscopy analysis, we showed that human recombinant prorenin induces a significant increase of SMC migration, starting from a concentration of 50 pg/mL (10 210 M), similar to that measured in human serum (173 pg/mL) 27 and plasma (109 pg/mL), 28 thereby supporting the pathophysiological relevance of the action of prorenin observed in vitro. On this matter, it will be relevant to determine the concentration of prorenin within tissues, and in particular, within the arterial wall. This is of interest because, through its interaction with PRR, human prorenin can be activated by non-proteolytic means, 4, 5, 29, 30 thereby triggering PRR phosphorylation and biological action. Although the in vivo significance of prorenin-mediated SMC migration acting via the PRR is not yet known, and it is premature to draw definitive conclusions, it is tempting to speculate that this new biological action of prorenin, a pro-enzyme previously considered without biological functions, may participate in the development of atherosclerotic lesions. On this matter, it is important to mention that all components of the classical renin-angiotensin system pathway have been identified in atherosclerotic lesions, suggesting a local activation of PRR in SMCs. 31 -34 Further studies with SMC-specific knockout mice will be required in order to define the role of PRR on atherosclerotic plaque development.
The requirement of the cell surface expression of PRR for the chemotactic action of prorenin on SMCs was then demonstrated by using two different approaches. The first was the use of a peptide that specifically inhibits the interaction of prorenin with the PRR. 2 The functional ability of the decoy peptide as a PRR blocker was previously demonstrated both in vivo 35 -38 and in vitro. 39, 40 The specificity of the inhibitory action of the decoy peptide R 10P IFLKRMPSI 19P on prorenin was also supported by the fact that, at the same concentration, the peptide did not alter the chemotactic response to PDGF-BB (data not shown). Moreover, the lack of inhibition of a scrambled peptide (LIRMRFPIKS) of the SMC migration in response to prorenin further supports the selectivity of this approach. Finally, the suppression of PRR expression with siRNA directly demonstrated the requirement of the PRR for the chemotactic action of prorenin on human SMCs. Efficient cell migration necessitates precise spatial and temporal control of different events, including the formation of a protrusion stabilized by integrin-mediated adhesions, within the focal adhesions, that establish structural and signalling linkages between the extracellular matrix and the actin cytoskeleton. Subsequently, actomyosin contractility drives forward propulsion, and then adhesions are disassembled to allow cell movement. pp125 FAK is an important regulator of cell migration, 41, 42 and calpain-mediated cleavage of pp125 FAK appears to function in both assembly and disassembly of adhesions. 43 By measuring the F-actin distribution and paxillin staining, we observed that after 10 min stimulation, prorenin induces membrane ruffles and protrusion, associated with an increase in focal adhesion size, as assessed by paxillin staining. The kinetics of Rac1 and RhoA activation appears to be slower than that observed for the variation in size of the focal adhesions, although both proteins were shown to be active after 10 min of stimulation, with a maximal activity after 30 min. At a later time point (60 min), the size of focal adhesions, and the distribution of paxillin, RhoA, and to some extent Rac1, appeared to return to basal levels when pp125 FAK cleavage occurred. By using selective Rac1 and Rho kinase inhibitors, and siRNA directed to either Rac1 or RhoA, we have also demonstrated that the activity of both small GTPase proteins is required for the prorenin-dependent chemotactic effect. 17, 20 The pp125 FAK processing represents a marker of focal adhesion disassembly required for rear release. The involvement of pp125 In conclusion, we demonstrated that prorenin, through the PRR, induces SMC migration and motility. Thus, we propose that the chemotactic action of prorenin is mediated by the activation of RhoA and Rac1, and by pp125 FAK cleavage, pivotal regulators of cell migration events and focal adhesion assembly (see Supplementary material online, Figure SII ).
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